0 items

in your cart
$0.00

Prescription Drug Search

Strengths available for Sutent:

Sutent 12.5mg
Sutent 25mg
Sutent 50mg

Search for a drug:

 

Browse Alphabetically:

A · B · C · D · E · F · G · H · I · J · K · L · M · N
O · P · Q · R · S · T · U · V · W · X · Y · Z · #

Information about ExpressMedsCanada.com

SSL Secured Website Certified Global Pharmacy Network Hacker Proof: Safe Shopping Experience 5th Anniversary 2002-2007

List of countries where we can ship Sutent:

  • Algeria
  • Antigua and Barbuda
  • Armenia
  • Australia
  • Bahamas
  • Bahrain
  • Bangladesh
  • Belarus
  • Belize
  • Bermuda
  • Bolivia
  • Chile
  • China
  • Cyprus
  • Czech Republic
  • Ecuador
  • Finland
  • Gibraltar
  • Guam
  • Iceland
  • India
  • Korea, Republic of
  • Korea, South
  • Lithuania
  • Malta
  • Monaco
  • Panama
  • Paraguay
  • Philippines
  • Russian Federation
  • Singapore
  • Slovakia
  • Sri Lanka
  • Sweden
  • Switzerland
  • Taiwan
  • Thailand
  • Turkey
  • United Kingdom, UK
  • United States, US
View All Countries

Latest news releases on Sutent:

Pfizer Provides Topline Results From Phase 3 Study Of Torisel(R) As Second-Line Treatment In Advanced Renal Cell Carcinoma (RCC) - Marketwatch

About SUTENT((R)) (sunitinib malate) SUTENT is an oral multi-kinase inhibitor approved for the treatment of advanced renal cell carcinoma (RCC), gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib ...

Pfizer says EU recommends approval of Inlyta - msnbc.com

A European Union advisory committee recommended that Inlyta be approved as a treatment for advanced renal cell carcinoma in patients who were not helped by treatment with Pfizer's drug Sutent or with cytokines, a class of cancer medications that ...

Disappointing Data on Pfizer Drug - Zacks.com

The company is looking to expand Torisel’s label for use in advanced renal cell carcinoma (RCC) patients whose disease has progressed while on or after being treated with Sutent. Results from the phase III INTORSECT (B1771003) study showed that Torisel ...

Disappointing Data on Pfizer Drug - Analyst Blog - Boston Globe

The company is looking to expand Torisel’s label for use in advanced renal cell carcinoma (RCC) patients whose disease has progressed while on or after being treated with Sutent. As far as the secondary endpoint -- overall survival -- was ...

Pfizer’s Axitinib gets positive opinion from CHMP for second-line treatment of advanced kidney cancer - pharmabiz.com

In January, axitinib was approved by the US Food and Drug Administration (FDA) as INLYTA. SUTENT is approved for gastrointestinal stromal tumours (GIST) after disease progression on or intolerance to imatinib mesylate, for advanced RCC, and for progressive ...

Pfizer Provides Topline Results From Phase 3 Study Of Torisel® As Second-Line Treatment In Advanced Renal Cell Carcinoma (RCC) - Yahoo Finance

Pfizer Inc announced today that the Phase 3 INTORSECT (B1771003) study, evaluating TORISEL ® (temsirolimus) in patients with advanced renal cell carcinoma (RCC) whose disease had progressed on or after SUTENT ® (sunitinib malate) therapy ...

Pfizer’s Torisel Misses Endpoints in Renal Cell Carcinoma Trial Testing Second-Line Setting - Genetic Engineering News

The trial compared Torisel and Nexavar in patients whose disease had progressed on or after treatment with the company’s approved drug Sutent. Although PFS was numerically higher in patients treated with Torisel, the difference was not ...

Research and Markets: Afinitor (Pancreatic Cancer) - Analysis and Forecasts to 2020 - CNBC

Sutent, GV1001, Afinitor, Avastin, AMG479, Abraxane, Masitinib, Gemzar, Nexavar, S-1, Tarceva, Certican, Novartis For more information visit

BUYINS.NET: Market Maker Surveillance … - TMCnet

It also offers Zyvox for gram-positive pathogens; Premarin for menopausal symptoms; Sutent for renal cell carcinoma; Geodon/Zeldox for schizophrenia; Detrol/Detrol LA for overactive bladder; Zosyn/Tazocin, an intravenous antibiotic; Genotropin ...

Pfizer Provides Topline Results From Phase 3 Study Of Torisel As Second-Line Treatment - The FINANCIAL

The FINANCIAL -- Pfizer Inc announced that the Phase 3 INTORSECT study, evaluating TORISEL in patients with advanced renal cell carcinoma (RCC) whose disease had progressed on or after SUTENT therapy, did not meet the primary endpoint of prolonging ...

Customer Service
1-866-799-3435 - Use Discount Code 7500 | Contact Form
Copyright © 2012 ExpressMedsCanada.com All rights reserved. Disclaimer | Privacy Policy
Accepted Credit Cards and Payment: VISA, MASTERCARD and eCHECK